A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy

Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study

(2018) Craig M McDonald et al.   LANCET

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management

(2018) David J Birnkrant et al.   LANCET NEUROLOGY

Deflazacort vs prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post hoc analysis from the ACT DMD trial

(2018) Perry B Shieh et al.   MUSCLE & NERVE

A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial

(2018) Rebecca A. Crow et al.   Trials

Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study

(2018) John P Bourke et al.   BMJ Open

The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review

(2017) S. Ryder et al.   Orphanet Journal of Rare Diseases

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies

(2017) Andrea M. Reinig et al.   PHARMACOTHERAPY

Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy

(2016) Molly M. Lamb et al.   JOURNAL OF PEDIATRICS

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy

(2016) Robert C. Griggs et al.   NEUROLOGY

Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy

(2016) David Gloss et al.   NEUROLOGY

Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341)

(2015) Michael G. Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Duchenne muscular dystrophy

(2015) Eppie M Yiu et al.   JOURNAL OF PAEDIATRICS AND CHILD HEALTH

Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study

(2015) Luca Bello et al.   NEUROLOGY

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy

(2014) Sunkyung Kim et al.   JOURNAL OF CHILD NEUROLOGY